Search Result

Results for "

PPARγ agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (2) Angiotensin Receptor (4) Antibiotic (2) Bacterial (4) Bombesin Receptor (1) COX (1) Drug Derivative (1) Endogenous Metabolite (1) ERK (1) Fungal (2) HIF/HIF Prolyl-Hydroxylase (2) Keap1-Nrf2 (1) LXR (2) PPAR (41) Reference Standards (4)
By Research Areas:	Cancer (16) Cardiovascular Disease (4) Endocrinology (4) Infection (2) Inflammation/Immunology (11) Metabolic Disease (28) Neurological Disease (6)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-163294

PPARγ agonist 10	PPAR	Metabolic Disease
PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .

HY-169404

PPARγ agonist 15	PPAR	Metabolic Disease
PPARγ agonist 15 (Compound 7c) is an agonist for PPARγ. PPARγ agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC₅₀ of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model .

HY-146439

PPARγ agonist 4	PPAR	Cancer
PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ. PPARγ agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib .

HY-173622

PPARγ agonist 18	PPAR	Metabolic Disease Endocrinology
PPARγ agonist 18 (Compound (I)) is a PPARγ inhibitor (K_D: 3.75 μM). PPARγ agonist 18 can inhibit CDK5-mediated phosphorylation of PPARγ at Ser245. PPARγ agonist 18 can be used in insulin resistance research .

HY-146438

PPARγ agonist 3	PPAR	Cancer
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .

HY-146482

PPARγ agonist 6	PPAR	Cancer
PPARγ agonist 6 (Compound 12) is a potent and selective agonist of PPARγ. PPARγ agonist 6 has the potential for the research of cancer diseases .

HY-146731

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

HY-168719

PPARγ agonist 16	PPAR	Inflammation/Immunology
PPARγ agonist 16 (Compound 4G) is the agonist for PPARγ, that competitively binds to LBD domain of PPARγ with IC₅₀ of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model .

HY-153982

PPARγ agonist 8	PPAR	Metabolic Disease
PPARγ agonist 8 is an agonist of PPARγ. PPARγ agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC₅₀ of 0.2 μM .

HY-159944

PPARγ agonist 14	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC₅₀=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .

HY-146480

PPARγ agonist 5	PPAR	Cancer
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases .

HY-176214

PPARγ agonist 19	PPAR COX	Metabolic Disease
PPARγ agonist 19 (Compound 5e) is a PPARγ agonist. PPARγ agonist 19 has an IC₅₀ of 11.27 μM against COX-1 and an IC₅₀ of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction .

HY-146742

PPARγ agonist 2	PPAR	Metabolic Disease
PPARγ agonist 2 is a potent PPARγ partial agonist and can be used for metabolic disease research .

HY-116468

PPARγ agonist 11	PPAR	Metabolic Disease
PPARγ agonist 11 (compound 20) is a selective agonist of PPARγ (EC₅₀: 0.1 μM) .

HY-162320

PPARγ agonist 12	PPAR	Metabolic Disease
PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC₅₀s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .

HY-173166

PPARγ agonist 17	PPAR	Cancer
PPARγ agonist 17 (Compound C1) is a PPARγ agonist. PPARγ agonist 17 enhances PPARγ activity and blocks the cell cycle in G2/M phase, inhibits cell migration and induces apoptosis in HT-29 cells. PPARγ agonist 17 has a broad spectrum anti-proliferative activity in cancer cells with relatively low toxicity in normal cells which cannot cross the blood-brain barrier .

HY-147511

PPARγ agonist 7	PPAR	Others
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of PPARγ. PPARγ agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC₅₀, 4.34 μM) .

HY-15655

GW1929 Maximum Cited Publications 10 Publications Verification	PPAR	Neurological Disease Metabolic Disease
GW 1929 is an orally active *peroxisome proliferator-activated receptor-γ (PPARγ)* agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ*, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .

HY-110022

GW1929 hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
GW1929 hydrochloride is an orally active *peroxisome proliferator-activated receptor-γ (PPARγ)* agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis* and shows anti-inflammatory potential .

HY-14831

Arhalofenate 1 Publications Verification MBX 102; JNJ 39659100	PPAR	Metabolic Disease
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor *(PPAR)-γ*, used for the treatment of type 2 diabetes.

HY-139408

17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid 17-Oxo-DHA; 17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-DHA	PPAR Keap1-Nrf2	Metabolic Disease
17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid (17-Oxo-DHA) is a metabolite of lipoxygenase-mediated oxidation of DHA. 17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid is a PPARγ agonist and activates a Nrf2 dependent antioxidant reaction .

HY-N0246

Saikosaponin A 5 Publications Verification	LXR Bacterial	Inflammation/Immunology Cancer
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-120160

Darglitazone CP-86325	PPAR	Neurological Disease Metabolic Disease
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active *PPAR-γ* agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-14831A

(+)-Arhalofenate (+)-MBX 102; (+)-JNJ 39659100	PPAR	Metabolic Disease
(+)-Arhalofenate ((+)-MBX 102) is the less active enantiomer of Arhalofenate (HY-14831). Arhalofenate is a selective partial agonist of peroxisome proliferator-activated receptor *(PPAR)-γ*, used for the treatment of type 2 diabetes .

HY-N0246R

Saikosaponin A (Standard)	Reference Standards LXR Bacterial	Metabolic Disease Inflammation/Immunology
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-138997

MBX-102 acid	PPAR	Metabolic Disease
MBX-102 acid is a selective partial *PPAR-γ* agonist. MBX-102 acid binds highly to plasma proteins, mainly serum albumin. MBX-102 acid can be used to study type 2 diabetes .

HY-120160A

Darglitazone Sodium CP 86325 Sodium	PPAR	Neurological Disease Metabolic Disease
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective *PPAR-γ* (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-113473

10-Nitrolinoleic acid	PPAR	Metabolic Disease Inflammation/Immunology Cancer
10-Nitrolinoleic acid is a potent *peroxisome proliferator-activated receptor γ (PPARγ) agonist. 10-Nitrolinoleic acid competes with [ ³H]Rosiglitazone for binding to PPAR-γ, with an IC₅₀* of 0.22 μM .**

HY-N6869

Dehydroabietic acid 1 Publications Verification	Antibiotic PPAR Bacterial Fungal	Infection Metabolic Disease Inflammation/Immunology Cancer
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-W341997

9-Octadecynoic acid	PPAR	Metabolic Disease
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .

HY-B0205

Candesartan 5 Publications Verification CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-N6869R

Dehydroabietic acid (Standard)	Antibiotic Reference Standards PPAR Bacterial Fungal	Infection Metabolic Disease Inflammation/Immunology Cancer
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-106181A

Rivoglitazone hydrochloride R-106056 hydrochloride	PPAR	Metabolic Disease
Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .

HY-B0205R

Candesartan (Standard) CV 11974 (Standard)	Reference Standards Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-154985

DSO-5a	PPAR Bombesin Receptor ERK	Metabolic Disease
DSO-5a is a potent, selective, orally active BB₃ agonist. DSO-5a is a representative DMAKO-00 derivative compound. DSO-5a upregulates *ppar-γ* activity through BB₃ and activates ERK1/2 phosphorylation. DSO-5a can be used in diabetes-related research .

HY-B0205S

Candesartan-d4 CV-11974-d₄	Angiotensin Receptor	Others
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-B0205G

Candesartan CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (GMP) (CV 11974 (GMP)) is Candesartan (HY-B0205) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

HY-19394A

(E)-CLX-0921	PPAR	Metabolic Disease
(E)-CLX-0921 is the E-isomer of CLX-0921 (HY-19394). CLX-0921 is an orally active PPARγ agonist with an IC₅₀ of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes .

HY-N7624

Methyl oleanonate 3-Oxoolean-12-en-28-oic acid methyl ester	PPAR	Cancer
Methyl oleanonate is a natural triterpene PPARγ agonist isolated from the species of Pistacia lentiscus var. Chia . Methyl oleanonate is a modified oleanolic acid derivative with anti-cancer effects .

HY-19394

CLX-0921	PPAR	Metabolic Disease
CLX-0921 is an orally active PPARγ agonist with an IC₅₀ of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes .

HY-N0234

Bavachinin 5 Publications Verification 7-O-Methylbavachin; Bavachinin A	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-176243

15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester	Drug Derivative Endogenous Metabolite PPAR	Neurological Disease Inflammation/Immunology Cancer
15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester is a derivate of 15-Deoxy-Δ-12,14-prostaglandin J2 (HY-108568). 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-N0234R

Bavachinin (Standard) 7-O-Methylbavachin (Standard); Bavachinin A (Standard)	Amyloid-β Reference Standards PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

Cat. No.	Product Name	Type

HY-B0205G

Candesartan (GMP) CV 11974 (GMP)	Fluorescent Dye
Candesartan (GMP) (CV 11974 (GMP)) is Candesartan (HY-B0205) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

Candesartan (GMP)

CV 11974 (GMP)

Fluorescent Dye

Candesartan (GMP) (CV 11974 (GMP)) is Candesartan (HY-B0205) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

Cat. No.	Product Name	Type

HY-B0205G

Candesartan (GMP)

CV 11974 (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0246

Saikosaponin A 5 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Source classification Umbelliferae Plants Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Cancer	LXR Bacterial
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N6869

Dehydroabietic acid 1 Publications Verification	Infection Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-W341997

9-Octadecynoic acid	Leguminosae Paramacrolobium coeruleum (Taub.) J.Léonard Ketones, Aldehydes, Acids Source classification Plants	PPAR
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .

HY-N7624

Methyl oleanonate 3-Oxoolean-12-en-28-oic acid methyl ester	Triterpenes Pistacia lentiscus var. Chia other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer Anacardiaceae	PPAR
Methyl oleanonate is a natural triterpene PPARγ agonist isolated from the species of Pistacia lentiscus var. Chia . Methyl oleanonate is a modified oleanolic acid derivative with anti-cancer effects .

HY-N0234

Bavachinin 5 Publications Verification 7-O-Methylbavachin; Bavachinin A	Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N0246R

Saikosaponin A (Standard)	Triterpenes Terpenoids Source classification Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray	Reference Standards LXR Bacterial
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N6869R

Dehydroabietic acid (Standard)	Microorganisms other families Terpenoids Source classification Diterpenoids Plants	Antibiotic Reference Standards PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N0234R

Bavachinin (Standard) 7-O-Methylbavachin (Standard); Bavachinin A (Standard)	Monophenols Flavonoids Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants	Amyloid-β Reference Standards PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

Cat. No.	Product Name	Chemical Structure

HY-B0205S

Candesartan-d4
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PPARγ agonist

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products